Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
NCT04561102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 644
Last updated 2022-01-21
Summary
"This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis.
Results from the comparator EUA test will be provided to the collection site investigator or designated collection site study staff. No medical treatment, guidance on treatment decisions, nor medical care will be provided. "
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Diagnostic test for detection of SARS-CoV-2
The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
Sponsors & Collaborators
-
Helix OpCo, LLC
collaborator UNKNOWN -
Illumina, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-09-11
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- United States
Study Locations
More Related Trials
-
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
NCT05928507 ·Status: UNKNOWN
-
Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics
NCT05946538 ·Status: UNKNOWN ·Phase: NA
-
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
NCT06734741 ·Status: COMPLETED
-
Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)
NCT06360757 ·Status: TERMINATED
-
COVID SAFE: COVID-19 Screening Assessment for Exposure
NCT04508777 ·Status: COMPLETED
-
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)
NCT04906694 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
NCT05438602 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
NCT05787444 ·Status: UNKNOWN
-
Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient
NCT04595136 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
NCT04537208 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
NCT05668091 ·Status: COMPLETED ·Phase: PHASE2
-
Intranasal INNA-051 for Prevention of COVID-19 in Adults
NCT05118763 ·Status: WITHDRAWN ·Phase: PHASE2
-
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
NCT05074394 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
NCT05567952 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
NCT05372783 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection
NCT05697055 ·Status: UNKNOWN ·Phase: PHASE4
-
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
NCT04539262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Codivir in Patients With COVID-19
NCT04930861 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
NCT05596045 ·Status: WITHDRAWN ·Phase: PHASE1
-
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
NCT02487173 ·Status: COMPLETED ·Phase: NA
-
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
NCT05260437 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
NCT05785390 ·Status: TERMINATED ·Phase: PHASE2
-
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
NCT05218356 ·Status: RECRUITING ·Phase: PHASE2
-
Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
NCT05184101 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
NCT05603143 ·Status: TERMINATED ·Phase: PHASE3